Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
ZO

AMEX · ZOM

Zomedica Corp.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.10

Down-$0.00 (-0.21%)

Updated Sep 17, 2026, 2:01 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
95.35M
P/E ratio
-1.12
Dividend yield
0.00%
52-week range
— – —
Volume
790.94K
Avg. volume
8.54M

Price performance

ZOM price history

1M range · 0 trading sessions · Daily adjusted prices

ZOM does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ZOM news

The latest Smart Investors Daily articles mentioning ZOM.

Stock researchCompany · Overview

ZOM research

Overview

Company profile and research snapshot.

Company profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ZOM recent ratings
DateFirmRatingTarget
Jan 6, 2023Dawson JamesBuy—
Nov 16, 2020HC Wainwright & Co.Buy—
Jun 17, 2020HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

seekingalpha.com · Nov 21, 2025

Zomedica Corp. (ZOMDF) Q3 2025 Earnings Call Transcript

Zomedica Corp. (OTC:ZOMDF) Q3 2025 Earnings Call November 21, 2025 4:00 PM EST Company Participants Larry Heaton - President, CEO & Director Mike Zuehlke - Senior VP of Finance & Corporate Controller Presentation Unknown Executive Before we begin, I want to remind current and potential investors that we will be making various remarks about future expectations, plans and prospects that are considered forward-looking statements. There are risks that actual results may differ from these statements.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By